PART I Item 1. B usiness. Overview We are a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system. We believe this approach has the potential to effectively control diseases with high unmet need that are driven by excessive complement activation. We currently have two marketed d...
Q2 FY2026 — expected 2026-08-22
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-24 | 2025-12-31 | 0001193125-26-065179 | EDGAR | 122K words |
| 2025-02-28 | 2024-12-31 | 0000950170-25-029507 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0000950170-24-020614 | EDGAR | — |
| 2023-02-21 | 2022-12-31 | 0000950170-23-003438 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0001564590-22-007606 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001564590-21-008800 | EDGAR | — |
| 2020-02-27 | 2019-12-31 | 0001564590-20-007350 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-30 | 2025-09-30 | 0001193125-25-257374 | EDGAR | 30K words |
| 2025-07-31 | 2025-06-30 | 0000950170-25-100545 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0000950170-25-064976 | EDGAR | — |
| 2024-11-05 | 2024-09-30 | 0000950170-24-121062 | EDGAR | — |
| 2024-08-01 | 2024-06-30 | 0000950170-24-088938 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0000950170-24-053921 | EDGAR | — |
| 2023-11-01 | 2023-09-30 | 0000950170-23-057117 | EDGAR | — |
| 2023-07-31 | 2023-06-30 | 0000950170-23-035935 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0000950170-23-017819 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0000950170-22-022606 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0000950170-22-015500 | EDGAR | — |
| 2022-05-04 | 2022-03-31 | 0000950170-22-007374 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001193125-26-134916 | EDGAR | 67K words |
| 2026-03-02 | 0001193125-26-084156 | EDGAR | — |
| 2026-01-12 | 0001193125-26-010540 | EDGAR | — |
| 2025-07-01 | 0001193125-25-153429 | EDGAR | — |
| 2025-06-04 | 0001193125-25-134886 | EDGAR | — |
| 2025-04-21 | 0001193125-25-086304 | EDGAR | — |
| 2025-01-13 | 0001193125-25-005052 | EDGAR | — |
| 2024-08-08 | 0001193125-24-196465 | EDGAR | — |
| 2024-06-05 | 0001193125-24-155179 | EDGAR | — |
| 2024-05-14 | 0001193125-24-137743 | EDGAR | — |
97 total filings indexed. 68 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001492422 |
| Ticker | APLS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.apellis.com |
| Listed | 2017-11-09 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/APLS (~200 tokens, structured JSON with cryptographic provenance)